Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

413
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
413
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

79
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
79
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

176
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
176
Pleural Effusion II: Symptoms and Management01:28

Pleural Effusion II: Symptoms and Management

161
Pleural Effusion Overview
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
161
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

355
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
355
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

152
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
152

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Empagliflozin versus dapagliflozin for kidney outcomes in stage 3 chronic kidney disease: a propensity score-matched multi-center cohort study.

BMC nephrology·2026
Same author

Phosphate Disorders in Cancer.

Kidney360·2026
Same author

The podocyte slit-diaphragm: target of anti-nephrin antibodies.

Current opinion in nephrology and hypertension·2026
Same author

Corrigendum to "Randomized Controlled Trial on the Efficacy of Reduced-Dose Cyclical Corticosteroids and Cyclophosphamide in Primary Membranous Nephropathy" [<i>Kidney International Reports</i> Volume 10, Issue 11, November 2025, Pages 3785-3795].

Kidney international reports·2026
Same author

Circulating Testican-2 and MGT5A are Markers of Membranous Nephropathy.

Kidney international reports·2026
Same author

Associations of Podocyte-Derived Protein Biomarkers With Foot Process Effacement and Kidney Histopathologic Lesions in Individuals With Glomerular Disease.

Kidney medicine·2025

Related Experiment Video

Updated: Jun 18, 2025

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

382

Membranous Nephropathy: Updates on Management.

Joyita Bharati1, Dia Rose Waguespack2, Laurence H Beck3

  • 1Nephrology Section, Department of Medicine, Boston Medical Center, Boston, MA.

Advances in Kidney Disease and Health
|July 31, 2024
PubMed
Summary
This summary is machine-generated.

Membranous nephropathy, a cause of nephrotic syndrome, is diagnosed noninvasively using autoantibodies to M-type phospholipase A2 receptor. Rituximab is a key treatment for high-risk patients, alongside supportive care.

Keywords:
AutoantibodiesMembranous nephropathyNephrotic syndromePLA2RRituximab

More Related Videos

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
07:38

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin

Published on: May 6, 2018

8.4K
Optimizing Isolation and Purification of Murine Glomerular Mesangial Cells
04:46

Optimizing Isolation and Purification of Murine Glomerular Mesangial Cells

Published on: March 7, 2025

205

Related Experiment Videos

Last Updated: Jun 18, 2025

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

382
Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
07:38

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin

Published on: May 6, 2018

8.4K
Optimizing Isolation and Purification of Murine Glomerular Mesangial Cells
04:46

Optimizing Isolation and Purification of Murine Glomerular Mesangial Cells

Published on: March 7, 2025

205

Area of Science:

  • Nephrology
  • Immunology
  • Pathology

Background:

  • Membranous nephropathy is a leading cause of nephrotic syndrome in adults.
  • Antibody deposition in podocytes triggers kidney damage through complement activation.
  • M-type phospholipase A2 receptor (PLA2R) is a primary target antigen.

Purpose of the Study:

  • To review antigens involved in membranous nephropathy.
  • To discuss the disease's natural history and clinical management.
  • To outline current immunosuppressive treatment guidelines.

Main Methods:

  • Review of literature on membranous nephropathy antigens and treatments.
  • Analysis of diagnostic advancements, including autoantibody testing.
  • Evaluation of therapeutic strategies, including supportive care and immunosuppression.

Main Results:

  • Autoantibodies to PLA2R enable noninvasive diagnosis and monitoring.
  • Supportive care (RAS inhibitors, statins, diuretics) is crucial.
  • Rituximab is a first-line immunosuppressant for high-risk patients, with exceptions.

Conclusions:

  • Understanding antigens is key to diagnosing and managing membranous nephropathy.
  • Personalized treatment balances supportive care with immunosuppression.
  • Noninvasive diagnostics and targeted therapies improve patient outcomes.